PubMed Health⌕ Search

Biomedical subjects

E Szeruda-Rudzka

Publications and source records attributed to E Szeruda-Rudzka.

5 recordsLinked to original sources
PubMed1979

Application of a combined rosette-fluorescent test in studies on leukemia cells.

In 13 healthy blood donors and 42 patients with leukemia and lymphosarcoma, the combined rosette-fluorescent test allowed simultaneous evaluation of peripheral blood lymphocytes and leukemia cells for presence of membrane immunoglobulins and sheep erythrocyte receptors. In healthy subjects, the mean value for T cells was 68 +/- 9%, for B cells 16 +/- 5%, for nonreceptor cells 15 +/- 8%, and for cells possessing both markers 0.6 +/-0.8%. In cases of acute leukemia, nonreceptor cells predominated (59 +/-24%), and values for T cells were usually low (19 +/- 13%). In chronic lymphocytic leukemias and lymphosarcoma, B and "null" cells usually predominated more or less. In all patients values for double-receptor cells were low. The combined test proved to be a convenient method for simultaneous evaluation of both markers. It is also useful for recognizing blastic leukemia cells devoid of both receptors and for determing values for T and B lymphocytes.

B-Lymphocytes↗
PubMed1978

Lymphocyte subpopulations bearing different surface markers in non-Hodgkin lymphoma.

Lymphoid cells isolated from peripheral blood and lymph nodes were examined by using the rosette test with sheep erythrocytes (E), the immunofluorescent staining of the surface immunoglobulins (SmIg), the rosette test with mouse C 57 BL erythrocytes (Em and a combined test (SmIg + E). These studies were performed in 143 patients with various subtypes of non-Hodgkin lymphoma and in 110 controls. In the control group the following percentage of cell types was obtained: 1) blood (n = 110): T-68 +/- 12, B- 20 +/- 3, O- 11 +/- 7, BT- 1 +/- 1.4, Em+ cells--9 +/- 7, C3+ cells--21 +/- 3, 2) lymph nodes (n = 23): T- 66 +/- 10, B- 17 +/- 10, O- 15.7 +/- 9, BT- 0.8 +/- 1.7. In non-Hodgkin lymphoma lymph nodes a statistically significant increase of null and B cells- was noted in comparison to the controls (p less than 0.001). Similar changes were observed in the blood of non-Hodgkin lymphoma patients in which the leukocyte count exceeded 10(3)/microliter, whereas in the cases with low leukocythosis the B-T values were within the nomal range. It is concluded that the marker studied does allow to differentiate in most cases between the non-Hodgkin lymphoma and other disorders of the lymphoid system. They also give additional information about the more exact nature of the lymphoid malignancies.

Binding Sites↗